The Output
Our process is able to identify a pool of likely compounds with known medicinal properties which act on active and modulatory sites of metabolically relevant proteins and, coupled with predictive proteonomics and glyconomics, are highly likely to match the physionomic profile of a target user population for a desired indication.
​
These factors are modeled and tested for predictive power and iteratively adjusted to provide a proposed supplement formulation that is optimized for safety and effectiveness.
The Technology
WAI's technology has been used in the past for drug development, medical device development, closed loop physiological control systems, and bioinformatics applications for clients. The WAI architecture provides the output of a full chemistry department in a lean, semi-virtual environment.
Pools of Potential Compounds
Screened Against Published Literature & Known Chemical Libraries
Structure/Activity analyses are conducted against known binding targets in the body
Predictors are identified, then fed into AI System
WAI brings the same scientific rigor used in drug development to supplement formulation, ensuring solutions that are safer and more tailored to your individual needs.
First Proof of Concept
Using our process, we developed a simple and effective formulation for appetite control.
​
Won't Supplements (TM) has been shown to support safe and effective appetite control in male baby boomers, resulting in up to 30 lbs of weight loss over 6 months, representing up to 11.6% of total body weight loss (TBWL; data WAI internal), a number comparable to some published results using GLP-1 injectables such as Wegovy.
Unique Opportunities for Won't
-
Won't supports the maintenance of weight-loss from GLP-1s.
Studies show that after stopping GLP-1s, patients usually gain back the weight they lost
-
Won't helps keep the appetite suppressed after stopping GLP-1 therapy and is a natural supplement that can be taken by otherwise healthy individuals indefinitely.
​
